AbbVie Inc. ranks below the peer group median, with a split structural profile: strong stability, but weak profitability and valuation. The trend setup is mixed, though short-term momentum remains constructive. Current market behavior is broadly confirming the weaker structural profile.
Peer-relative scores, weakest to strongest
AbbVie is a global biopharmaceutical company specializing in immunology, oncology, neuroscience, and eye care. Its portfolio includes blockbuster drugs such as Humira, Skyrizi, and Rinvoq.
Robust capital efficiency and profitability—evident in a 10.17% ROIC and a 34.1% operating margin—position AbbVie as a leader in operational quality. Yet, the premium valuation (forward P/E 12.9x, peer median 25.1x) is under pressure, as regulatory and product concentration risks affect the company’s long-term outlook.
Internally, AbbVie’s 10% year-over-year revenue growth and €4.2bn in net income indicate that its core business remains fundamentally solid, supporting ongoing capital returns. This revenue momentum, achieved despite biosimilar headwinds and margin pressure, counters some market concerns. However, the premium pricing (valuation score: 1/100) reflects investor caution regarding AbbVie’s exposure to regulatory reforms and the transition away from Humira reliance.
External context affects the outlook. The company’s strategic pivot to Skyrizi and Rinvoq in immunology, alongside the FDA approval of Epkinly in oncology, shows progress in diversifying revenue streams. These advances support the execution story. However, biosimilar competition for Humira and ongoing regulatory pressures—such as drug pricing reforms and patent expirations—mean the premium has not yet stabilized. Regulatory uncertainty continues to weigh on sector sentiment, affecting AbbVie and its peers alike.
Compared to peers, AbbVie’s profitability and recent growth are stronger than many, but its premium valuation is not unique. Companies like Gilead and Bristol-Myers also trade at elevated multiples, though with less revenue diversification and lower recent growth. AbbVie’s risk profile is more pronounced than many peers, partly driven by factors specific to its product transition and regulatory exposure.
A more defensible premium would require sustained revenue diversification beyond Humira and a material easing of regulatory uncertainty. Supporting improvement would include continued expansion of the oncology and immunology portfolios with positive milestones. Until then, AbbVie carries a valuation not yet fully anchored.
Break down ABBV's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.